1-2 of 2
Toshio Kaneko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study

Free
Nigishi Hotta, MD, Takayoshi Toyota, MD, Kempei Matsuoka, MD, Yukio Shigeta, MD, Ryuichi Kikkawa, MD, Toshio Kaneko, MD, Akira Takahashi, MD, Kimiya Sugimura, MD, Yasuo Koike, MD, Jun Ishii, MD, Nobuo Sakamoto, MD, The SNK-860 Diabetic Neuropathy Study Group
Journal: Diabetes Care
Diabetes Care 2001;24(10):1776–1782
https://doi.org/10.2337/diacare.24.10.1776
Published: 01 October 2001
View articletitled, Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study
Open the PDF for Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study in another window
Journal Articles

Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy

Free
Yasuhiko Iwamoto, MD, Kinori Kosaka, MD, Takeshi Kuzuya, MD, Yasuo Akanuma, MD, Yukio Shigeta, MD, Toshio Kaneko, MD
Journal: Diabetes Care
Diabetes Care 1996;19(2):151–156
https://doi.org/10.2337/diacare.19.2.151
Published: 01 February 1996
View articletitled, Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
Open the PDF for Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy in another window